TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) — Greenridez 2.0 Acquisitions Corp. (the “ Company “) is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma (“ Lophos ”).
Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports Lophos Pharma’s belief in Peyote’s potential to treat indications ranging from weight loss and addiction, to anxiety and depression. Greenridez 2.0 Acquisitions Corp. will be operating as Lophos Holdings going forward and has appointed Claire Stawnyczy as Chief Executive Officer.
Claire gained substantial pharmaceutical experience from her work in the biotechnology industry before transferring to cannabis in 2017. During Claire’s time as CEO of Canalytica Corp., a business management and regulatory consulting firm, she led numerous Licensed Producers in achieving regulatory compliance and streamlining business operations. Claire’s experience, drive and respect for the Peyote plant and its history not only make her uniquely qualified to lead the Lophos team, but to be an excellent ambassador for this important and nascent segment of the psychedelics market.
“I look forward to leading the Lophos team and respectfully adding to Peyote’s proud history,” said Claire Stawnyczy, CEO of Lophos. “We are excited by Health Canada’s recent amendment to the special access program and look forward to supplying patients in the future.”
